CHRN is a weak-quality, momentum-failing name with no clear engine edge; the risk case dominates and the position is flagged for exit rather than accumulation.
Thesis pillars
- Quality Below Floor→Stable
- Momentum Gate Failure→Stable
- No Clear Engine Edge→Stable
- +1 more pillar — see the Why tab for full reasoning
ChronoScale Holdings Corporatio (CHRN) Stock Analysis
Breakout setup
Technology · Information Technology Services
Sell if holding. Engine safety override at $21.85: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation.
Ekso Bionics Holdings (now ChronoScale Corporation) designs and markets wearable robotic exoskeletons — including EksoNR, Ekso Indego Therapy, and Ekso Indego Personal — for rehabilitation and mobility. Most sales come from Enterprise Health products used in clinical settings,... Read more
Sell if holding. Engine safety override at $21.85: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. Score 4.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on 8k serious 2.05. Suitability: aggressive.
About ChronoScale Holdings Corporatio
About ChronoScale Corporation
Ekso Bionics Holdings' Enterprise Health exoskeletons — EksoNR, cleared by the FDA for spinal cord injury, brain injury, stroke, and multiple sclerosis rehabilitation, and Ekso Indego Therapy — generate the majority of company revenue from clinical settings, while its Personal Health division sells the Ekso Indego Personal device for home and community use. As of December 31, 2025, the company had signed reimbursement-channel partnerships with National Seating & Mobility, Bionic Prosthetics & Orthotics Group (serving 14 states), and Ottobock Patient Care, with over 50 individuals identified as qualifying for potential Medicare reimbursement.
The company earns revenue from device sales, EksoCare extended-warranty and service contracts, fee-for-service repairs, and training programs, with Personal Health sales dependent on a complex third-party reimbursement process spanning VA, Medicare, Medicaid, and private insurers that can involve lengthy delays between delivery and payment settlement. To reduce manufacturing costs, the company is transitioning a significant amount of its production to third-party manufacturers under agreements it has not structured as long-term supply contracts, and it separately distributes MediTouch Inc.'s BalanceTutor rehabilitation system under an exclusive U.S. distribution arrangement expected to launch in early 2026. The exoskeleton business itself, however, became secondary to a much larger corporate event: on February 15, 2026 the company signed a Contribution and Exchange Agreement to combine with Applied Digital Corporation's cloud computing subsidiary, Applied Digital Cloud, in a deal the 10-K said would leave APLD's contributing entity owning approximately 97% of the combined company.
Show full overview
That business combination closed on May 5, 2026, when Applied Digital Cloud became a wholly owned subsidiary and the company changed its name to ChronoScale Corporation, consistent with the roughly 97% equity stake the 10-K had flagged for APLD's Contributor entity. Less than a month later, on May 29, 2026, ChronoScale's board committed to divesting the entire Ekso Bionics exoskeleton business described throughout this filing, in order to focus solely on the cloud business acquired from APLD — meaning the medical-device operations this 10-K details are, as of the most recent 8-K, no longer the company's intended core business.
See also: Technology · Information Technology Services
From ChronoScale Corporation's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-25Recent Developments — ChronoScale Holdings Corporatio
Latest news
- NEWS Northland Capital Markets Initiates Coverage On ChronoScale Holdings with Outperform Rating, Announces Price Target of $ — benzinga Sep 18, 2026 positive
- NEWS ChronoScale Announces Plans With Microsoft For 50-MW AI Compute Deployment In North America — benzinga Aug 27, 2026 positive
- NEWS Nutanix Collaborates With ChronoScale To Jointly Offer Enterprise-Ready AI Infrastructure — benzinga Aug 18, 2026 positive
- NEWS 12 Information Technology Stocks Moving In Tuesday's Intraday Session — benzinga Jul 21, 2026 neutral
- NEWS AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday — benzinga Jul 20, 2026 positive
Generated 2026-09-25T04:47:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierthird-party manufacturers10-K Item 1A: 'In order to reduce manufacturing costs, we intend to transition a significant amount of our manufacturing processes to third parties.'
- HIGHSupplierMediTouch Inc.10-K Item 1: 'MediTouch BalanceTutor is developed and manufactured by MediTouch Inc. ("MediTouch") and will be exclusively distributed by us in the United States.'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.01HIGHEkso Bionics Holdings closed its Business Combination with Applied Digital Corporation's cloud subsidiary, Applied Digital Cloud Corporation, under the February 15, 2026 Contribution and Exchange Agreement. Cloud became a wholly owned subsidiary, APLD's Contributor entity received newly issued shares (~97% of the combined company), and the company changed its name to ChronoScale Corporation.SEC filing →
- 2026-06-04Item 2.05MEDIUMChronoScale's board committed on May 29, 2026 to divest its wholly owned Ekso Bionics, Inc. subsidiary (the legacy exoskeleton business) to focus solely on its cloud business, expecting completion in the first fiscal quarter, with material but not-yet-estimated severance, lease-termination, and transaction charges.SEC filing →
- 2026-06-30Item 5.02LOWChronoScale expanded its Board from seven to eight members and appointed Andrew Cordell Schaap as director and Audit and Related Party Transactions Committee member, replacing Douglas Miller only on the Audit Committee (Miller remains on the board). Schaap received a 200,000-share RSA vesting over two years; a pre-existing data center lease with a company where Schaap is CEO was disclosed as informational.SEC filing →
- 2026-05-20Item 5.02LOWAn 8-K/A disclosed Phantom PSU awards granted November 5, 2025 to executives Scott G. Davis (185,000 units), Jerome Wong (40,000), and Jason Jones (32,000), vesting on a Change in Control plus a stock-price goal and settled in cash; the Board amended related terms on May 14, 2026 (further detail not available).SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -70.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.85: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. Prior stop was $20.32. Score 4.2/10, moderate confidence.
Take-profit target: $27.20 (+24.5% upside). Prior stop was $20.32. Stop-loss: $20.32.
Concentration risk — Supplier: MediTouch Inc.; Quality below floor (1.3 < 4.0).
ChronoScale Holdings Corporatio trades at a P/E of N/A (forward -11.9). TrendMatrix value score: 0.0/10. Verdict: Sell.
8 analysts cover CHRN with a consensus score of 4.0/5. Average price target: $32.
What does ChronoScale Holdings Corporatio do?Ekso Bionics Holdings (now ChronoScale Corporation) designs and markets wearable robotic exoskeletons — including...
Ekso Bionics Holdings (now ChronoScale Corporation) designs and markets wearable robotic exoskeletons — including EksoNR, Ekso Indego Therapy, and Ekso Indego Personal — for rehabilitation and mobility. Most sales come from Enterprise Health products used in clinical settings, plus Personal Health devices reimbursed through VA, workers' compensation, and Medicare, and it plans to distribute MediTouch's BalanceTutor system.